(Corticosteroid Therapy in Uveitis )Corticosteroid Therapy in Uveitis

13/11/2026   Share :        
117  

Corticosteroids are among the most important first-line treatments for controlling uveitis because of their potent anti-inflammatory effects. They reduce inflammatory cell infiltration within the eye and help prevent complications that may lead to vision loss. The choice of corticosteroid, route of administration, dosage, and duration of treatment depends on the anatomical location, severity, underlying cause, and clinical response. Infectious causes must be excluded before corticosteroids are used as sole therapy. 1. Treatment of Anterior Uveitis Anterior uveitis is primarily treated with topical corticosteroid eye drops. Prednisolone Acetate 1% is one of the commonly preferred medications. In mild cases, one drop may be administered every six hours. In moderate to severe inflammation, one drop every one to two hours may be required during the active phase. Steroid tapering should begin after clear clinical improvement in anterior chamber cells. The frequency of administration is gradually reduced according to the clinical response, usually over several weeks. Cycloplegic eye drops, such as Cyclopentolate or Atropine, may also be prescribed to relieve pain and prevent posterior synechiae. 2. Treatment of Intermediate Uveitis In intermediate uveitis, topical corticosteroids alone are generally insufficient to control inflammation within the vitreous. Periocular corticosteroid injections, particularly Posterior Sub-Tenon Injections, may be used. Triamcinolone Acetonide or Methylprednisolone at a concentration of 40 mg/mL may be administered, commonly using 1 mL, according to the clinical condition and treatment protocol. In severe or bilateral cases, especially those associated with cystoid macular edema, systemic corticosteroid therapy may be required. Oral Prednisone is commonly initiated at 0.5–1 mg/kg/day, depending on disease severity. 3. Treatment of Posterior Uveitis Treatment depends on the severity of inflammation and its effect on the retina, choroid, and macula. In noninfectious, sight-threatening cases, oral Prednisone may be initiated at 0.5–1 mg/kg/day. More severe cases may require 1–1.5 mg/kg/day under specialist supervision. Intravitreal corticosteroid therapy may also be considered. One option is the Dexamethasone Intravitreal Implant (0.7 mg), particularly in cases of inflammatory macular edema or when topical therapy is insufficient. 4. Treatment of Panuveitis Panuveitis involves inflammation of the anterior, intermediate, and posterior parts of the uvea. Therefore, it often requires a more comprehensive treatment approach. In moderate to severe cases, oral Prednisone may be initiated at 0.5–1 mg/kg/day, with doses of 1–1.5 mg/kg/day considered in severe, sight-threatening disease. In fulminant cases, intravenous Methylprednisolone at 500–1000 mg daily for three days may be considered, followed by oral Prednisone with a gradual taper 5. Duration of Treatment and Steroid Tapering Corticosteroid doses should not be reduced until adequate control of inflammation and clear clinical improvement have been achieved. Gradual tapering is essential to minimize the risk of rebound inflammation. A commonly used example of oral Prednisone tapering after inflammatory control is: From 60 to 30 mg: reduce by 10 mg weekly. From 30 to 15 mg: reduce by 5 mg weekly. From 15 to 7.5 mg: reduce by 2.5 mg weekly. Below 7.5 mg: reduce by 1–2.5 mg every one week to one month, depending on disease stability. This is an illustrative regimen rather than a mandatory schedule. Chronic uveitis may require a considerably slower taper. Systemic corticosteroids administered for more than 2–3 weeks should not be discontinued abruptly because of the risk of hypothalamic-pituitary-adrenal axis suppression. Long-term treatment with Prednisone doses exceeding 7.5–10 mg daily is generally undesirable. If doses above approximately 7.5 mg daily are required for more than three months, steroid-sparing immunomodulatory therapy should be considered. Options include Methotrexate, Mycophenolate Mofetil, and Adalimumab, depending on the underlying disease. 6. Monitoring and Complications Regular follow-up is essential and should include intraocular pressure measurement, examination for cataract formation, assessment of intraocular inflammatory activity, and retinal evaluation, including OCT when indicated. Patients receiving systemic corticosteroids also require monitoring of blood pressure, blood glucose, body weight, and bone health, particularly during prolonged treatment. Conclusion Corticosteroid treatment in uveitis depends on the anatomical location and severity of inflammation. Topical corticosteroids are the mainstay of treatment for anterior uveitis, whereas intermediate, posterior, and panuveitis frequently require periocular, intravitreal, or systemic therapy. Treatment should begin with an effective dose and be tapered gradually according to the clinical response. Steroid-sparing immunomodulatory therapy should be considered in chronic or recurrent cases to minimize long-term corticosteroid exposure. University of Al-Mustaqbal – The First and Leading Private University